Also found in: Acronyms.


A gene on chromosome 17q11.2-q12 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ERBB2 has no ligand-binding domain and thus cannot bind growth factors; it does, however, bind to other ligand-bound EGF receptor family members, forming a heterodimer, stabilising ligand binding and enhancing kinase-mediated activation of downstream signalling pathways (e.g., those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase).

Molecular pathology
ERBB2 amplification and overexpression commonly occurs in breast and ovarian cancers.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


Human epidermal growth factor receptor 2, a receptor that plays an essential role in cell proliferation and differentiation. It is a member of a family of transmembrane tyrosine kinases. The 20 to 25 percent of breast cancers that over-express HER2 have a high rate of recurrence in the first two or three years after surgery. The HER2 gene is on the short arm of chromosome 17. Over-expression of this gene increases the malignancy of affected cancer cells, enhancing growth and proliferation and increasing their metastatic tendency. The monoclonal antibody drug trastuzumab (Herceptin) which blocks this receptor is effective in reducing the dangers of HER2-expressing breast cancers.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
ten Kate, "Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study," Journal of Clinical Pathology, vol.
"It is our belief that if we can discover therapies which block the activity of WASH, we can develop more effective treatments, which prevent the growth of HER2 breast tumors and their spread.
Genentech scientists, having cloned the first human HER2 gene earlier, create Herceptin by humanizing a mouse antibody directed at HER2.
Another innovation from Roche is HER2 franchise or T-DM1 for women with previously treated HER2-positive advanced breast cancer (second line setting).
Gene expression profiling studies have identified at least four categories of breast cancer: luminal A, luminal B, HER2 overexpressing, and basal-like or triple negative (TN) [1, 2].
Figure 1 [13] shows the main transduction pathways regulated by the four HER family members--EGFR, HER2, HER3, and HER4.
The HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy.
HER2 stands for Human Epidermal Growth Factor Receptor 2, a protein that recognizes and binds to a specific growth factor.
To quantify the impact of the new ASCO/CAP guideline in daily practice, we applied the HER2 FISH classifications criteria produced in 2007, 2013, and 2018 (1, 2, 5) to a consecutive series of 880 breast cancer samples collected during the past 4 years in our institution and selected for FISH analysis according to in-house policy (6) or as requested by clinicians (Figure).
HER2 is a member of the epidermal growth factor family and is over expressed in malignancies of breast, ovarian, gastric, Colorectal, pancreatic and endometrial cancers (4).